Redeye gives a short comment on the directed issue in Ascelia.
Redeye is encouraged to see Tagmaster presenting strong numbers across the board.
* Sales +1%, EBITA adj. +13% vs. FactSet consensus * Strong organic growth, but adj.
* Adj. EBIT well above estimates at SEK 45m * Underlying performance strong, but keep an eye out for...
Redeye provides its initial take on Heliospectra’s Q1 2026 results.
AVTECH's Q1 2026 report confirmed last week's pre-announced figures without adding material new info...
Vaisala’s Q1 revenue continued to grow 7% y/y in constant currencies, and the EUR 20.
SRV issued a positive profit warning, raising its estimate for revenue and operative operating profi...
Tekova’s Q1 results exceeded expectations, reinforcing confidence that operating profit will land in...
Xvivo demonstrated once again that it is back on track and generating positive free cash flow.
Xspray Pharma is close to achieving commercialisation, with two FDA decisions expected this summer.
Duni reported a softer Q1, with sales down 5.3% y/y (-1% organic).
Actic's Q1 looks solid and came in in line with our expectations.
Redeye comments on Dynavox’s Q1 report released earlier this morning, which delivered a solid start ...
Vitrolife reported softer revenues relative to our estimates, as we had projected a more modest fx-i...
Inderes delivered Q1 numbers almost perfectly in line with our estimates.
Following the release of the Q1 2026 report, Physitrack's CEO, Henrik Molin, joins us to discuss the...
Redeye returns with a revised forecast following Binero’s Q1’26 trading update, which showed sequent...
Net sales and adjusted EBITA were below consensus in Q1.
Fiskars' Q1 results were strong, driven by the Fiskars business area (BA Fiskars).